[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hydrocortisone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hydrocortisone":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100451592","phase-2-corticosteroids-to-treat-pancreatitis-100451592",false,"NCT05160506","Corticosteroids to Treat Pancreatitis","Corticosteroids to Reduce Inflammation in Severe Pancreatitis: A Randomized, Controlled Study","CRISP","Inclusion Criteria:\n\n1. Adult (≥18 years)\n2. Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.\n3. Admission or planned admission to an intensive care unit\n4. SOFA disease severity score ≥3 (or at least 3 points above a known baseline)\n\nExclusion Criteria:\n\n1. Known diagnosis of autoimmune pancreatitis\n2. Existing clinical indication for corticosteroids at a dose \\>5mg of oral prednisone daily (or equivalent)\n3. Contraindication to receiving corticosteroids\n4. Protected populations (prisoners)\n5. Pregnancy","ALL","18 Years","99 Years",{"count":21,"type":22},86,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.",[28,29,30,31],"Pancreatitis","Pancreatitis, Acute","Corticosteroid","Hydrocortisone",[33,34,35],"Bedside index of severity in acute pancreatitis","Sequential Organ Failure Assessment","Randomized Controlled Trial","RECRUITING","2026-02-16",{"date":39,"type":40},"2026-02-18","ACTUAL",{"date":42,"type":40},"2022-03-06",{"date":44,"type":22},"2027-04",{"name":46,"class":47},"Beth Israel Deaconess Medical Center","OTHER"]